Dreadful Efficacy Rates of Sinovac Covid Vaccine in Brazil Suggests Longer Revenue Streams and Higher Sustainable Pricing for mRNA Based Vaccines are Likely.

The announcement by Sinovac that their Covid vaccine has an official success rate of just 50.34%, which is suspect due to the requirement of a minimum 50% threshold by the WHO for approval for sale to countries lacking their own domestic drug approval process. As real world efficacy is lower than test rates, due to the nature of the testing process, it appears that the Sinovac formulation is a failure and should be shelved.

it appears that Moderna may benefit developing evidence that conventional vaccine formulations to inoculate against covid might be largely ineffective, as was postulated by this author some months ago.